Related Experiment Videos
Prostate cancer prevention: what do we know now and when will we know more?
Ian M Thompson1, Joseph Basler, Deborah Hensley
1Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. thompsoni@uthscsa.edu
Clinical Prostate Cancer
|March 26, 2004
Summary
Extensive clinical trials are evaluating finasteride, vitamin E, and selenium for prostate cancer prevention. Results from major studies are expected soon, potentially offering new strategies to reduce cancer risk.
Area of Science:
- Urologic oncology
- Cancer prevention research
Background:
- Prostate cancer prevention is a key focus in urologic oncology.
- Over 30,000 men are involved in US clinical trials for prevention.
Purpose of the Study:
- To assess the effectiveness of key interventions like finasteride, vitamin E, and selenium in preventing prostate cancer.
- To provide clinicians with evidence-based strategies for risk reduction.
Main Methods:
- Completion of end-of-study prostate biopsies for the Prostate Cancer Prevention Trial.
- Rapid accrual for the Selenium and Vitamin E Cancer Prevention Trial.
- Ongoing phase II and biomarker-modulation studies exploring other interventions.
Main Results:
- Definitive answers regarding finasteride, vitamin E, and selenium are anticipated.
- Results from large-scale prevention trials are nearing completion.
Conclusions:
- Major clinical trials are nearing completion, poised to offer significant insights into prostate cancer prevention.
- The findings are expected to guide clinical practice in reducing prostate cancer risk.